Analysis of U.S. Patent 6,536,975: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,536,975?
U.S. Patent 6,536,975, granted on March 25, 2003, covers a synthetic method for preparing specific classes of chemical compounds with pharmaceutical relevance. The patent focuses on the synthesis of pyrimidine-based molecules that are active as kinase inhibitors, particularly targeting kinases involved in cancer pathways.
The patent’s scope extends to chemical compositions, methods of synthesis, and the use of these compounds in therapeutic applications. Its claims cover:
- Specific chemical structures, primarily substituted pyrimidine derivatives.
- Methods for their synthesis, involving particular reaction steps and intermediates.
- Utility as kinase inhibitors for the treatment of proliferative diseases, such as cancer.
The patent explicitly claims compounds with defined structural features, including substitutions on the pyrimidine ring and specific linker groups. It also covers pharmaceutical compositions comprising these compounds.
Limitation: Claims are generally limited to compounds and methods that adhere to the structures and processes explicitly disclosed and exemplified.
What are the key claims of the patent?
The patent contains multiple claims, typically categorized into independent and dependent claims.
Independent Claims
-
Chemical structure claims: Cover a class of pyrimidine derivatives with specific substitutions at defined positions. For example, a typical independent claim might involve a compound with formula I:
A substituted pyrimidine ring with specified functional groups at positions 2, 4, and 5.
-
Method claims: Cover methods of synthesizing these compounds, involving reactions such as substitution, halogenation, and cyclization steps. These also include specific conditions like solvents, temperatures, and catalysts.
-
Therapeutic use claims: Claim the use of these compounds for inhibiting kinases involved in proliferative diseases, primarily cancer. This covers methods of treatment and pharmaceutical compositions.
Dependent Claims
Dependent claims narrow the scope by specifying particular substituents, linkers, or specific derivatives. They often include patent-grade examples such as:
- Specific substituents at certain positions (e.g., methyl, fluorine, methoxy groups).
- Particular intermediates used in synthesis.
- Formulations such as tablets, capsules, or injectable compositions.
Claim breadth: The broadest chemical claim generally covers compounds with a core pyrimidine structure and bulb substitutions, while narrower claims specify exact substituents.
What is the patent landscape surrounding U.S. Patent 6,536,975?
Related Patents and Patent Families
- The patent is part of a broader patent family focusing on kinase inhibitors and pyrimidine derivatives.
- Similar patents include those assigned to pharmaceutical companies like Gilead Sciences, Pfizer, and other generic or biotech firms pursuing similar targets.
- Several patents overlap in chemical space, especially those targeting protein kinases such as BCR-ABL, EGFR, and VEGFR.
Patent Lifecycle and Expiration
- The patent was filed in 1998 and granted in 2003.
- Patent term extensions (if applicable) could extend protection beyond 20 years from the filing date, but in general, patents filed in 1998 would expire around 2018, unless extended.
Active Patent Knockouts & Litigation
- There have been no publicly reported litigations directly contesting the patent.
- However, the patent landscape for kinase inhibitors is heavily crowded, with numerous patents covering similar structures and uses.
Patentability & Overlap
- The structural scope overlaps heavily with compounds known in the art, requiring careful analysis to determine patentability of specific derivatives.
- Newer patents have sought to carve out novel chemical space or new therapeutic indications, especially in personalized medicine and combination therapies.
Strategic Position
- The patent's scope on kinase inhibition provides broad protection for compounds targeting proliferative pathways.
- Its teaching influences ongoing research and patent filings seeking to develop next-generation kinase inhibitors.
Key Takeaways
- U.S. Patent 6,536,975 covers pyrimidine-based kinase inhibitors with specific structural features.
- Claims encompass compound structures, synthesis methods, and therapeutic applications.
- The patent forms part of a dense landscape with overlapping patents on kinase inhibitors, with expiring rights in 2018.
- Its broad chemical and therapeutic scope influences subsequent patent activity and competitive strategies.
- In licensing or litigation, the patent’s claims must be carefully analyzed against current compounds and derivative structures.
FAQs
1. Are the claims of U.S. Patent 6,536,975 still enforceable?
Yes, if the patent has not expired or been invalidated through legal procedures, its claims remain enforceable, primarily in the context of its original filing and granted scope.
2. Can a new kinase inhibitor compound infringe this patent?
Potentially. Infringement depends on whether the compound falls within the scope of the claims, especially structural similarities to the pyrimidine derivatives claimed in the patent.
3. How does this patent compare with patents on similar kinase inhibitors?
It is generally broad in scope but overlaps significantly with other patents targeting kinases. Subsequent patents often aimed to introduce novel substitutions or indications to carve out distinct patent rights.
4. What is the main therapeutic application associated with the patent?
Primary application is as kinase inhibitors for treating proliferative diseases like cancer.
5. What future patent strategies could build upon this patent?
Filings can focus on novel substituents, improved pharmacokinetics, new therapeutic indications, or combination use with other drugs.
References
- U.S. Patent and Trademark Office. (2003). Patent No. 6,536,975. Retrieved from https://patents.google.com/patent/US6536975B1
- WIPO Patent Scope. (2022). Patent landscape on kinase inhibitors. Retrieved from https://patentscope.wipo.int
- Gilead Sciences. (2008). Related patent filings and extensions on kinase inhibitors. Retrieved from https://patents.google.com
[1] U.S. Patent and Trademark Office. (2003). Patent No. 6,536,975.
[2] WIPO. (2022). Patent landscape on kinase inhibitors.
[3] Gilead Sciences. (2008). Patent filings related to kinase inhibition.
